Fig. 2From: Improved patient-reported outcomes in patients with psoriatic arthritis treated with abatacept: results from a phase 3 trialSF-36 PCS and MCS change from baseline (weeks 16 and 24, overall population). *Statistically significant difference. Dotted line represents MCID (≥ 2.5). CI confidence interval, MCID minimal clinically important difference, MCS mental component summary, PCS physical component summary, SE standard error, SF-36 Short Form-36Back to article page